Medicare Updates: What Retirees Need to Know in February 2026

Medicare cost shifts for 2026 are modest but material for retirees: Part A deductible rose from $1,676 to $1,736, Part B premium increased from $185.00 to $202.90 and its deductible from $257 to $283, and the Part D out-of-pocket maximum rose to $2,100 from $2,000. Negotiated prices for ten prescription drugs (including Januvia, Eliquis, Jardiance and Xarelto) may lower drug spend for affected enrollees, while most telehealth coverage reverted to pre‑public‑health rules as of Jan. 30, 2026, potentially reducing virtual-care utilization; Medicare Advantage enrollees retain an open-enrollment window through March 31, 2026. These developments imply slightly higher healthcare cost exposure for retirees, selective revenue pressure/opportunity for drugmakers and managed-care plans, and modest policy-driven shifts in utilization trends.

Analysis

Market structure: Insurers and PBMs (UNH, HUM, CVS, CI) are the likely near-term beneficiaries — higher Part B premiums and deductible hikes raise demand for Medicare Advantage and supplemental plans and increase ARPU; expect MA enrollment reallocation during the open-enrollment window through Mar 31, 2026, creating a 4–8 week flow window. Drug manufacturers of the 10 negotiated medicines face downward revenue pressure; Part D out-of-pocket cap rising to $2,100 mutes patient price shock but shifts payer economics toward plan sponsors and PBMs who can capture negotiated savings.

Risk assessment: Tail risks include a regulatory reversal or litigation expanding negotiated pricing (high impact on pharma) or a court reinstating broader telehealth coverage (rebounding TDOC), each realizable within 3–12 months. Short-term (days–weeks) volatility centers on MA enrollment reports and CMS guidance; medium-term (quarters) risk is earnings-season recognition of lower drug revenue vs PBM margin gains; long-term risk is political pressure forcing faster price controls across larger formularies.

trade implications: Tactical plays: overweight diversified insurers and PBMs (UNH 2–4% portfolio, CVS 1–2%) ahead of MA enrollment close and Q1 results; short or hedge pure-telehealth TDOC (buy 3–6 month puts 10–20% OTM) as policy removal reduces addressable market by an estimated 20–40% near term. Use pair trade: long UNH / short TDOC to isolate policy-exposure; consider covered-call writing on UNH to collect premium until Apr earnings.

contrarian angles: Consensus underestimates PBM capture of savings and overestimates permanent telehealth destruction — telehealth could rebound via Medicare carve-outs or commercial uptake, creating a mean-reversion trade in 6–18 months. Also, negotiated-price hit to pharma may be localized; look for mispricings in large-cap pharma that diversify revenue (avoid blanket shorts) and scout long-dated TDOC calls as a low-dollar, high-upside asymmetric bet if policy noise subsides.

Key Decisions for Investors

• Establish a 2–4% overweight long position in UnitedHealth (UNH) within 1–2 weeks to capture MA enrollment inflows and Optum PBM benefit; hedge by selling 1–2 month covered calls (10–15% OTM) until Apr 2026 earnings, exit or reassess if UNH falls >10% or MA enrollment growth is < +1 pct point vs prior quarter.
• Add 1–2% long exposure to CVS Health (CVS) to play PBM/formulary capture of negotiated savings; target hold 3–6 months and trim on a +8% move; reduce if CMS expands negotiated list beyond 10 drugs (monitor CMS releases weekly).
• Initiate a short/hedge position on Teladoc (TDOC): buy 3–6 month puts 10–20% OTM sized to limit portfolio exposure to 0.5–1%; thesis: Medicare telehealth rollback cuts addressable Medicare-driven visits by ~20–40% near term. Cover or unwind if a federal court or Congressional rider restores broad telehealth coverage within 90 days.
• Construct pair trade — long UNH (2%) / short TDOC (0.75%) — to isolate policy-driven spread; target spread capture over 1–3 months around Mar 31 enrollment and Apr earnings; close on spread contraction >50% or if enrollment flows contradict expectations.